GNI Group Ltd 2160

Morningstar Rating
¥2,292.00 +26.00 (1.15%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

2160 is trading at a LOCK|$p<!k premium.
Price
¥2,266.00
Fair Value
LOCK|z%.rBp<?@
Uncertainty
LOCK|%JsV
1-Star Price
LOCK|bw.n%@B?v&
5-Star Price
LOCK|qN.Tgy%Mk!#
Economic Moat
LOCK|$%
Capital Allocation
—

Trading Information

Previous Close Price
¥2,266.00
Day Range
¥2,165.00–2,361.00
52-Week Range
¥2,003.00–3,740.00
Bid/Ask
¥2,291.00 / ¥2,292.00
Shares Outstanding
65.81M
Market Cap
¥150.85B
Volume/Avg
4M / 2M

Key Statistics

Price/Earnings (Normalized)
299.16
Price/Sales
3.55
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases. The company's business activities are divided into the pharmaceutical business and the medical device business. In the pharmaceutical business, the company conducts research and development, manufacturing, and sales of development compounds, mainly I-Suru, which is sold in the Chinese market, and F351, which has completed clinical trials. In the medical device business, the company develops, manufacture, and sell medical devices (biomaterials) based in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
1,040

Valuation

Metric
2160
Price/Earnings (Normalized)
299.16
Price/Book Value
2.32
Price/Sales
3.55
Price/Cash Flow
—
Price/Earnings
2160

Financial Strength

Metric
2160
Quick Ratio
1.07
Current Ratio
1.54
Interest Coverage
−1.28
Quick Ratio
2160

Profitability

Metric
2160
Return on Assets (Normalized)
−5.02%
Return on Equity (Normalized)
−10.53%
Return on Invested Capital (Normalized)
−4.84%
Return on Assets
2160

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|<XWLplLOCK|xxTh$136B
Regeneron Pharmaceuticals Inc
REGN
LOCK|^>&qSW<LOCK|>FZ$?$99B
Moderna Inc
MRNA
LOCK|GQ&<&<LOCK|%^M$87B
argenx SE ADR
ARGX
LOCK|&G?RvCLOCK|%PJ$61B
BeOne Medicines Ltd ADR
ONC
LOCK|&bK>Mb!LOCK|$%$48B
Royalty Pharma PLC Class A
RPRX
LOCK|Q^$y#pRLOCK|%CvY#$31B
Incyte Corp
INCY
LOCK|W%#@tVLOCK|>kC$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|m&>?>#bLOCK|#?mnP$21B
BioNTech SE ADR
BNTX
LOCK|L$!S^$dLOCK|XZj$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|$>G?#CLOCK|q^$15B

Sponsor Center